Trading Update

In brief · summary, not quotable

FY25 revenue and loss both beat expectations; contracted revenue for FY26 reaches record levels.

vs expectations: ahead

Total Income FY25 £834k (prior £571k)
Loss after Tax FY25 £419k (prior £609k)
Contracted revenue carried into FY26 £593k (prior £500k)
Average contract wins FY24-FY25 £1m per year (prior £613k per year average prior five years)
Grant Income expected FY26 £60k

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that its Total Income and Loss after Tax will exceed market expectations for the financial year ending 30 June 2025 (FY25).

Based on unaudited end of year accounts for FY25, the Company is projecting to finish the year with a Total Income of £834k and Loss after Tax of £419k, both metrics being ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46% and a reduction in Loss after Tax of approximately 31%, reflecting the positive growth trajectory of the business and effective cost management.

The Company continues to build its pipeline with the average total value of contract wins over FY24 and FY25 reaching a record high of over £1m per year, a 63% increase on the yearly average over the previous five years. The Company started the current financial year ending 30 June 2026 (FY26) with approx. £593k of contracted revenue that is projected to be recognised within the year. This compares to approximately £500k worth of contracts carried forward from the year ended 30 June 2023 (FY23) into FY24, an 18.6% year-on-year increase. We are therefore confident that further revenue growth can be achieved in FY26.

In addition, the Company expects that £60k worth of Grant Income will be recognised in FY26.

The Company is also generating momentum across its key growth initiatives:

Biometrics service line: June 2025 announcement of the Company's first two Biometrics contracts worth £111k and recruitment of Head of Biometrics, Jesse Thissen
Diversification of client base: 31% of all contract awards in FY25 were from new clients, compared to 17% over the prior six years.
Expansion into new therapeutic areas: 50% of projects delivered in FY25 were in therapeutic areas outside oncology, compared to an average of 5% over the previous three years
Personalised Medicine - Recently announced expanded relationship with DoseMe Inc and Implementation of the Company's Dosing software onto the DoseMeRx Platform, and progress of the PREDICT-ONC trial.

Dr Peter Sargent, CEO of Physiomics, commented:

"I am thrilled that the changes we've made here at Physiomics are starting to have a positive effect on the Company's performance. Not only will we exceed expectations for FY25, but we've started FY26 with record levels of contracted revenue yet to be recognised and are generating significant momentum across our key growth initiatives."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.